Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...

In the results, dual GLP-1/GIP agonist Zepbound (tirzepatide) outperformed GLP-1 agonist Wegovy (semaglutide) on all weight-loss endpoints at 72 weeks among patients with obesity or who were ...

Personally, I've been on Zepbound for nearly 10 weeks now and I've lost over 25 pounds thanks to a combination of the injection, diet, exercise and, of course, the advice of my doctor.

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha.